Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP566064.RARh1w_Ee8hTVJJbrcTAp1qn-lHXedCn2F8TU6pqKm5Qs130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP566064.RARh1w_Ee8hTVJJbrcTAp1qn-lHXedCn2F8TU6pqKm5Qs130_provenance.
• NP905141.RAQbtZJXaBQeqakoXaM7A1KtsnrOIsTR0nYo2_QIBnFMc130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP905141.RAQbtZJXaBQeqakoXaM7A1KtsnrOIsTR0nYo2_QIBnFMc130_provenance.
• NP666862.RAB6UiXq2m-T0IwhARXSBsWT2_8aieTbV63pCdLb0xoQE130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP666862.RAB6UiXq2m-T0IwhARXSBsWT2_8aieTbV63pCdLb0xoQE130_provenance.
• NP585839.RAlEHahrVZ5XbUX2Bv6VhOUKjcdMECo4marGJnGNp9-ic130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP585839.RAlEHahrVZ5XbUX2Bv6VhOUKjcdMECo4marGJnGNp9-ic130_provenance.
• NP572198.RA9xsBRiusV9O2MEoPWvquX0L1prW2UzD4O1sgz-M7-HM130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP572198.RA9xsBRiusV9O2MEoPWvquX0L1prW2UzD4O1sgz-M7-HM130_provenance.
• NP585914.RAyHdQZPLpDtVgorayO2ve0prQYs-diPhz3bbU1J3v7pQ130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP585914.RAyHdQZPLpDtVgorayO2ve0prQYs-diPhz3bbU1J3v7pQ130_provenance.
• NP847910.RABHvI2x7gg4f1iKdog_71-_8gEVu-t4I1_QcWCFMsgJ4130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP847910.RABHvI2x7gg4f1iKdog_71-_8gEVu-t4I1_QcWCFMsgJ4130_provenance.
• NP840012.RAqUG3LWBRtxo1IpP0qoy0xUuNI1GoZhDC0D3QBv6AheY130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP840012.RAqUG3LWBRtxo1IpP0qoy0xUuNI1GoZhDC0D3QBv6AheY130_provenance.
• NP799441.RAoUOxz2AJqA2RnjNcBr6QG5f69APyKRboQxeuZtvi8po130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP799441.RAoUOxz2AJqA2RnjNcBr6QG5f69APyKRboQxeuZtvi8po130_provenance.
• NP349122.RAxHqJ-wV-T0aw1w78fCF3aD5FCq-O6OPkGlKCGZdbEqA130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP349122.RAxHqJ-wV-T0aw1w78fCF3aD5FCq-O6OPkGlKCGZdbEqA130_provenance.
• NP683323.RA1gLB_LmhEtpgHmxfbeEuPp7DiygjUWQnFiDu72Hll9A130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP683323.RA1gLB_LmhEtpgHmxfbeEuPp7DiygjUWQnFiDu72Hll9A130_provenance.
• NP868053.RAzbzsQ_9pihTL7RMA3C2sJm_QOSj8YM1fO2h8yl11rAM130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP868053.RAzbzsQ_9pihTL7RMA3C2sJm_QOSj8YM1fO2h8yl11rAM130_provenance.
• NP262947.RAz2xpZmwe132OhiiY1Z-yadwYHwjVaPiONFF7hCTtIJY130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP262947.RAz2xpZmwe132OhiiY1Z-yadwYHwjVaPiONFF7hCTtIJY130_provenance.
• NP804523.RANFjc4GndHunsThXNicL_NiGZwlbYaAShr2hh0RqPRLY130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP804523.RANFjc4GndHunsThXNicL_NiGZwlbYaAShr2hh0RqPRLY130_provenance.
• NP887301.RAM0cm_ue3mLptTTnCC0comzeLmmdRWI8BoViGXOB9qg8130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP887301.RAM0cm_ue3mLptTTnCC0comzeLmmdRWI8BoViGXOB9qg8130_provenance.
• NP538221.RA-X0z7X8ExCGfKzLZZare2-mwA-Xa3RvOA9GNQFQOZqk130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP538221.RA-X0z7X8ExCGfKzLZZare2-mwA-Xa3RvOA9GNQFQOZqk130_provenance.
• NP844745.RAbSq8ZfZq44X0bJWCQ2KrTolUnUX44Pe7Netdlxly9g0130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP844745.RAbSq8ZfZq44X0bJWCQ2KrTolUnUX44Pe7Netdlxly9g0130_provenance.
• NP847860.RAd8HOcXpRwEzeR3GnHN322PnVfsXqshFIxUfexy_2uyM130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP847860.RAd8HOcXpRwEzeR3GnHN322PnVfsXqshFIxUfexy_2uyM130_provenance.
• NP620366.RA2YihuQV1qAzBAxZYu0oD1kepdXBhbTd54hHE1bQb16E130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP620366.RA2YihuQV1qAzBAxZYu0oD1kepdXBhbTd54hHE1bQb16E130_provenance.
• NP620412.RA-luW2S76X6-2Vqih3eSos1TUvtK4TIcdSCNqcGib-hI130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP620412.RA-luW2S76X6-2Vqih3eSos1TUvtK4TIcdSCNqcGib-hI130_provenance.
• NP817371.RAXLDt1uOhE4WZk1Q3BPCycmyUVfMYtcTrqyZLHg6LjUQ130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP817371.RAXLDt1uOhE4WZk1Q3BPCycmyUVfMYtcTrqyZLHg6LjUQ130_provenance.
• NP844699.RA0O2f5vriHB7hVESxIt9l3HL8BkGU0Y5qS10GwDkG7SA130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP844699.RA0O2f5vriHB7hVESxIt9l3HL8BkGU0Y5qS10GwDkG7SA130_provenance.
• NP873606.RAwQdsK6FfG1K256r7fXOYwhu7baOgOqX-YGcqTQ-Q0LM130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873606.RAwQdsK6FfG1K256r7fXOYwhu7baOgOqX-YGcqTQ-Q0LM130_provenance.
• NP772280.RA9JwBA5HQMXGaupP-Xhs4mtZBlN0E1bKZAIq_90GgB_I130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP772280.RA9JwBA5HQMXGaupP-Xhs4mtZBlN0E1bKZAIq_90GgB_I130_provenance.
• NP772289.RA2eSv_5ckRgMCI1GZR6ytRWKVM-ocYkwyubswV4cO1CY130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP772289.RA2eSv_5ckRgMCI1GZR6ytRWKVM-ocYkwyubswV4cO1CY130_provenance.
• NP772290.RA423KrMX3IBkXWjIXgTNnCZjikGlDMwydqiROfvt-FxM130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP772290.RA423KrMX3IBkXWjIXgTNnCZjikGlDMwydqiROfvt-FxM130_provenance.
• NP772294.RA7qQLi_ZY0TBHXOag29b4nYFLvzkaj8gpZsdJ7lLNcOg130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP772294.RA7qQLi_ZY0TBHXOag29b4nYFLvzkaj8gpZsdJ7lLNcOg130_provenance.
• NP772279.RAZ4xZ_ARh4YFH1HU2Aj8Z5aVsMGwgrtUhdkbMsGbiX8E130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP772279.RAZ4xZ_ARh4YFH1HU2Aj8Z5aVsMGwgrtUhdkbMsGbiX8E130_provenance.
• NP772283.RAYIwZsFe17STt-9SHIZn_EaXHx2416pmzcS9J0dAfNYg130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP772283.RAYIwZsFe17STt-9SHIZn_EaXHx2416pmzcS9J0dAfNYg130_provenance.
• NP772285.RAWvaOM-63gfXoRSVA22ic6BdyzwqgT5grIVM_orLkYxo130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP772285.RAWvaOM-63gfXoRSVA22ic6BdyzwqgT5grIVM_orLkYxo130_provenance.
• NP772287.RAfyQR42LKAFhOyHgL5B_B1iczI9R6MlYpqCCBCKxElPw130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP772287.RAfyQR42LKAFhOyHgL5B_B1iczI9R6MlYpqCCBCKxElPw130_provenance.
• NP817332.RAIpfRhog2MilYs3obKOX5JO8zJF2WPTjNPA3lRrR0R7g130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP817332.RAIpfRhog2MilYs3obKOX5JO8zJF2WPTjNPA3lRrR0R7g130_provenance.
• NP772291.RAPgWZvHRG6Mdp478IsefqYbHtqSsrBZU7XYdyiAGN7iA130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP772291.RAPgWZvHRG6Mdp478IsefqYbHtqSsrBZU7XYdyiAGN7iA130_provenance.
• NP334123.RApKUiHV64weDo18kkt0QVfluaQHJSbdXncEiJuhPdzfI130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP334123.RApKUiHV64weDo18kkt0QVfluaQHJSbdXncEiJuhPdzfI130_provenance.
• NP334158.RAhW8T8gO3CgXxMOVfcbDqUahLqC2hWB1qMhR4V04wl9c130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP334158.RAhW8T8gO3CgXxMOVfcbDqUahLqC2hWB1qMhR4V04wl9c130_provenance.
• NP538283.RAqevsd68D6NHFMuneNaUvL_9Lq4RcZKiwUmU699ErYbk130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP538283.RAqevsd68D6NHFMuneNaUvL_9Lq4RcZKiwUmU699ErYbk130_provenance.
• NP873684.RAvhtdrGXH57OB6ygivxl-IBCCve1BUACs5K0sOd2K0_8130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873684.RAvhtdrGXH57OB6ygivxl-IBCCve1BUACs5K0sOd2K0_8130_provenance.
• NP772281.RAtGLFXTDBP94sGIYfOL8NFYVz4lnXT_RRYNjAMABzATM130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP772281.RAtGLFXTDBP94sGIYfOL8NFYVz4lnXT_RRYNjAMABzATM130_provenance.
• NP772282.RAnJo1I-ukYMqKEYB5fOCTXfBowvmp6kImltlxg7Mak5M130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP772282.RAnJo1I-ukYMqKEYB5fOCTXfBowvmp6kImltlxg7Mak5M130_provenance.
• NP772286.RAowdYhzRyBQ8j-r_nlQUOstKu5Shd4PlBtEIZz5zt1AI130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP772286.RAowdYhzRyBQ8j-r_nlQUOstKu5Shd4PlBtEIZz5zt1AI130_provenance.
• NP772288.RAteQH901he1mgiy7qFeCHRVyPvLcxBY8AKPDQcA1kixc130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP772288.RAteQH901he1mgiy7qFeCHRVyPvLcxBY8AKPDQcA1kixc130_provenance.
• NP772292.RAqsja9lITYaI2KAotgrrP34FcU8QnS-ZsL_YOJ4Jx784130_assertion description "[Our results from a large series of Chinese patients with breast cancer support that the ASCO/CAP 30% criterion may offer better results for assessing HER2 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP772292.RAqsja9lITYaI2KAotgrrP34FcU8QnS-ZsL_YOJ4Jx784130_provenance.